Omnicell Achieves HITRUST Implemented, 1-Year Certification to Manage Data Protection and Mitigate Cybersecurity Threats

FORT WORTH, Texas, -- December 1, 2023—Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced the company’s core business of medication management solutions and supporting infrastructure have earned Certified status for information security by HITRUST

HITRUST Implemented, 1-year (i1) Certified status demonstrates that the organization’s medication management solutions are appropriately managing risk through key information security controls and good cybersecurity hygiene. With this achievement, Omnicell joins an exclusive group of organizations that have earned HITRUST i1 Certification. Through alignment with and incorporation of best practices, and by leveraging the latest threat intelligence to maintain applicability with information security risks and emerging cyber threats, the HITRUST Implemented, 1-year (i1) Validated Assessment with Certification helps organizations address cybersecurity challenges and remain cyber resilient over time.

“HITRUST is continually innovating to find new and creative approaches to address challenges,” said Jeremy Huval, Chief Innovation Officer, HITRUST. “Omnicell’s HITRUST Implemented, 1-year Certification is evidence that they are at the forefront of industry best practices for information risk management and cybersecurity.”

About Omnicell

Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model in an effort to optimize financial and clinical outcomes across all settings of care. Through a comprehensive portfolio of automation and advanced services, Omnicell is uniquely positioned to address evolving healthcare challenges, connect settings of care, and streamline the medication management process. Healthcare facilities worldwide partner with Omnicell to help increase operational efficiency, reduce medication errors, improve patient safety, and enhance patient engagement and adherence, helping to reduce costly hospital readmissions. To learn more, visit omnicell.com.

OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.

Forward-Looking Statements

To the extent any statements contained in this press release deal with information that is not historical, these statements are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “plan,” “potential,” “anticipate,” “believe,” “estimate,” “seek,” “predict,” “project,” and variations of these terms and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to the occurrence of many events outside Omnicell’s control. Such statements include, but are not limited to the objectives and expected benefits of Omnicell’s products and services, including expectations regarding Omnicell’s Central Pharmacy Dispensing Service (and any implied financial impact with the foregoing). Actual results and other events may differ significantly from those contemplated by forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things, (i) Omnicell’s ability to take advantage of growth opportunities and develop and commercialize new solutions and enhance existing solutions, (ii) continued and increased competition from current and future competitors in the medication management automation solutions market and the medication adherence solutions market, (iii) unfavorable general economic and market conditions, including the impact and duration of inflationary pressures, (iv) reduction in demand in the capital equipment market or reduction in the demand for or adoption of our solutions, systems, or services, (v) delays in installations of our medication management solutions or our more complex medication packaging systems, (vi) risks related to Omnicell’s investments in new business strategies or initiatives, including its transition to selling more products and services on a subscription basis, (vii) risks related to failing to maintain expected service levels when providing our Advanced Services or retaining our Advanced Services customers, (viii) Omnicell’s ability to meet the demands of, or maintain relationships with, its institutional, retail, and specialty pharmacy customers, (ix) Omnicell’s ability to recruit and retain skilled and motivated personnel, and (x) other risks and uncertainties further described in the “Risk Factors” section of Omnicell’s most recent Annual Report on Form 10-K, as well as in Omnicell’s other reports filed with or furnished to the United States Securities and Exchange Commission (“SEC”), available at www.sec.gov. Forward-looking statements should be considered in light of these risks and uncertainties. Investors and others are cautioned not to place undue reliance on forward-looking statements. All forward-looking statements contained in this press release speak only as of the date of this press release. Omnicell assumes no obligation to update any such statements publicly, or to update the reasons actual results could differ materially from those expressed or implied in any forward-looking statements, whether as a result of changed circumstances, new information, future events, or otherwise, except as required by law.

OMCL-G